Please assess the completion status of the following clinical trial:

Trial Title: Fesoterodine Flexible Dose Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Overactive bladder symptoms for greater than or equal to 3 months.~* Mean urinary frequency of greater than or equal to 8 micturitions per 24 hours in bladder diary.~* Mean number of Urgency episodes greater than or equal to 3 per 24 hours in bladder diary.~Exclusion Criteria:~* Contraindication to fesoterodine (antimuscarinics).~* Known etiology of OAB (e.g., neurogenic, local urinary tract pathology).~* Previous history of acute urinary retention requiring catheterization or severe voiding difficulties in the judgment of the investigator, prior to baseline.~* Unable to follow the study procedures, including completion of self-administered bladder diary and patient reported outcome questionnaires.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fesoterodine (Double-Blind) (Type: EXPERIMENTAL): None
- Placebo (Double-Blind) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).